Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Pyelonephritis Clear all
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Pyelonephritis, Pyelonephritis Acute, Renal Sclerosis
Interventions
Quick MRI
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sylmar, California • Royal Oak, Michigan • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced May 21, 2026, 10:06 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia
Interventions
Not listed
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced May 21, 2026, 10:06 PM EDT
Not listed Phase 3 Interventional
View directory record Official record
Conditions
Complicated Urinary Tract Infection Including Acute Pyelonephritis
Interventions
Combination of Imipenem/Cilastatin and XNW4107, Meropenem
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection
Interventions
Vabomere, Best Available Therapy
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infections, Acute Pyelonephritis
Interventions
Cefepime/VNRX-5133 (taniborbactam), Meropenem
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Buena Park, California • Chula Vista, California • La Mesa, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced May 21, 2026, 10:06 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Urinary Tract Infections, Pyelonephritis Acute, Intraabdominal Infections
Interventions
Sulopenem
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
12 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced May 21, 2026, 10:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Pyelonephritis
Interventions
No intervention
Other
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
Interventions
ZTI-01, Piperacillin-tazobactam
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced May 21, 2026, 10:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Acute Pyelonephritis
Interventions
Cefepime-zidebactam (FEP-ZID), Meropenem
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Fort Myers, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced May 21, 2026, 10:06 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Pneumonia, Syncope, Congestive Heart Failure, Cellulitis, Pyelonephritis, AKI - Acute Kidney Injury, Diabetic Foot Infection, Osteomyelitis
Interventions
Next Day Clinic
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
cefepime/AAI101 combination, Piperacillin/tazobactam
Drug
Lead sponsor
Allecra
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Anaheim, California • Buena Park, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced May 21, 2026, 10:06 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Proteinuria
Interventions
Exposure to pyelonephritis
Other
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis
Interventions
Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin, Saline
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Ceftaroline fosamil and NXL104 (q8h), Ceftaroline fosamil and NXL104 (q12h), Doripenem, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
La Mesa, California • San Diego, California • Pensacola, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion, Dummy Tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Pyelonephritis Acute
Interventions
Cephalexin, Cephalexin or placebo
Drug
Lead sponsor
Brett A Faine
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Sylmar, California • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced May 21, 2026, 10:06 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Intra Abdominal Infections, Appendicitis Acute, Pyelonephritis, Diverticulitis, Epiploic Appendagitis
Interventions
TruNAV, an RNA-based blood test for host immune activation by infections
Diagnostic Test
Lead sponsor
True Bearing Diagnostics, Inc.
Industry
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 10:06 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Pyelonephritis, Complicated Urinary Tract Infection
Interventions
Meropenem-Vaborbactam, Antibiotics
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Industry
Eligibility
3 Months to 11 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Little Rock, Arkansas • Orange, California • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced May 21, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Infections, Urinary Tract
Interventions
GSK2251052, imipenem-cilastatin, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBPM-PI-HBr, Ertapenem, Dummy Infusion, Dummy tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
La Mesa, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced May 21, 2026, 10:06 PM EDT